Budesonide
- 1 lab
- Humans1
Outcomes
1Estimated glomerular filtration rate
no changein humans1
1 study
Estimated glomerular filtration rate
no changein humans1
Budesonide has no effect on estimated glomerular filtration rate in humans.
“eGFR was stable across the treatment period, with no significant change from baseline at nine months or at latest follow-up.”
HumansBiopsy-proven IgA nephropathy with near-universal RAS and SGLT2 inhibitor usetargeted-release formulationNine months and latest follow-up (median 11.2 months)n = 33
American journal of nephrology15 Oct 2026
Associations
2Adverse effects
upin humans1
1 study
Adverse effects
upin humans1
Budesonide is associated with adverse effects in humans (9 of 33 patients (27%) had a recorded adverse effect).
“An adverse effect was recorded in 9 of 33 patients (27%).”
HumansBiopsy-proven IgA nephropathy; retrospective ascertainmenttargeted-release formulationMedian follow-up 11.2 monthsn = 33
American journal of nephrology15 Oct 2026
Urine protein-to-creatinine ratio
downin humans1
1 study
Urine protein-to-creatinine ratio
downin humans1
Budesonide is associated with urine protein-to-creatinine ratio in humans (60% decrease (IQR 31–71%) in the intention-to-treat cohort).
“UPCR decreased by 60% (IQR 31-71%) in the ITT cohort (p < 0.001)”
HumansBiopsy-proven IgA nephropathy; RAS inhibitor use 94% and SGLT2 inhibitor use 91%targeted-release formulationMedian 11.2 monthsn = 33
American journal of nephrology15 Oct 2026